Lowering intraocular pressure (IOP) is the only intervention proven to prevent vision loss glaucoma. Treatment typically starts with medications, such as drops, that reduce intraocular pressure.
The most common glaucoma drops today (prostaglandin analogs, or PGAs) activate the prostaglandin FP receptor.4 This receptor is 1 of 9 prostanoid receptors that have been identified: FP, EP1-4, DP1, DP2, IP, and TP.5 FP activation leads to an increase in intracellular calcium ions and primarily lowers IOP through the uveoscleral outflow pathway.5 However, not all patients respond:
・~25% have inadequate responses to PGAs4
・~40% require adjunctive therapy4
Santen is also committed to preserving vision by pursuing the development of Sepetaprost, an eye drop that treats glaucoma with a novel mechanism of action.